News & Updates
Filter by Specialty:
TALENTACE supports atezolizumab + bevacizumab after TACE for HCC
Findings from the TALENTACE trial presented at ESMO GI 2025 support the combination of atezolizumab and bevacizumab after transarterial chemoembolization (TACE) for the treatment of individuals with systemically untreated, intermediate-to-high tumour burden, unresectable hepatocellular carcinoma (HCC).
TALENTACE supports atezolizumab + bevacizumab after TACE for HCC
12 Sep 2025
Poultry intake tied to increased risk of death from GI cancers, more so in men
A study from Italy suggests that the consumption of poultry – which includes all forms of chicken, turkey, duck, geese, guineas, quail, and pheasant as per the Dietary Guidelines for Americans 2020–2025 – ups the risk of death from gastrointestinal (GI) cancers, especially in men.
Poultry intake tied to increased risk of death from GI cancers, more so in men
11 Sep 2025
First-line durvalumab plus tremelimumab safe to use in unresectable HCC
The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.
